Evidence map›Paper›PMID 19571804›Full record

Trial reportClinical pharmacology and therapeutics2009

Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order.

J A Johnson, Y Gong, K R Bailey, R M Cooper-DeHoff, A B Chapman, S T Turner, G L Schwartz, K Campbell, S Schmidt, A L Beitelshees and 2 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical pharmacology and therapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00246519 (Pharmacogenomic Evaluation of Antihypertensive Responses), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00246519 phase4completednot on this map

Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

TypeinterventionalSponsorUniversity of FloridaRan2005 to 2010Enrolled1,701ConditionsHypertensionArmsHydrochlorothiazide, Atenolol
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Combination antihypertensive treatment: is initiation order important?Journal of clinical hypertension (Greenwich, Conn.) · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

J A JohnsonCollege of Pharmacy, University of Florida, Gainesville, Florida, USA. Johnson@cop.ufl.edu
Y Gong
K R Bailey
R M Cooper-DeHoff
A B Chapman
S T Turner
G L Schwartz
K Campbell
S Schmidt
A L Beitelshees
E Boerwinkle
J G Gums

Funding

MAYO CLINIC CENTER FOR TRANSLATIONAL SCIENCE ACTIVITIESUL1RR024150 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 2006 to 2011
$66.4M
WHITE MATTER AND COGNITION IN PARKINSON'S DISEASEM01RR000082 · NCRR · UNIVERSITY OF FLORIDA · PI FOOTE, KELLY D · 1985 to 2009
$29.7M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
X LINKED NYSTAGMUS SYNDROME WITH FEATURES OF ALBINISMM01RR000039 · NCRR · EMORY UNIVERSITY · PI VACCARINO, VIOLA · 1985 to 2007
$21.3M
Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI COOPER-DEHOFF, RHONDA M, JOHNSON, JULIE A. · 2005 to 2014
$20.7M
Uncoupling Protein Polymorphisms and Cardiometabolic Responses to Beta-BlockersK23HL091120 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI BEITELSHEES, AMBER L · 2008 to 2012
$661k
NCATS NIH HHS UL1 TR000454NCRR NIH HHS M01 RR000039NCRR NIH HHS M01 RR000082NCRR NIH HHS M01 RR00039NCRR NIH HHS M01 RR00082NCRR NIH HHS UL1 RR024150NCRR NIH HHS UL1 RR025008NHLBI NIH HHS K23 HL091120NIGMS NIH HHS U01 GM074492
6 · The paper itself

Abstract

For combination antihypertensive therapy with thiazide diuretics and beta-blockers, the effect of the order of initiation of the drugs on the outcome has not been tested. Patients with uncomplicated hypertension were randomized to receive either hydrochlorothiazide (HCTZ) or atenolol monotherapy, followed by addition of the alternative drug. Blood pressure (BP) responses were evaluated by race and order of drug initiation. A total of 368 participants received combination therapy. Among the participants, blacks showed a greater BP-lowering effect than whites did with HCTZ monotherapy (-13.0/-7.4 mm Hg vs. -8.0/-4.2 mm Hg, P < 0.001) but a smaller BP-lowering effect than did whites with atenolol monotherapy (-1.1/-2.9 mm Hg vs. -9.9/-9.2 mm Hg, P < 0.0001). These differences were not evident during combination therapy. However, both groups showed greater response to HCTZ + atenolol than to atenolol + HCTZ (-19.1/-14.2 mm Hg vs. -15.6/-11.3 mm Hg, P < 0.0001). Despite optimal dosing of HCTZ + atenolol, only two-thirds of the participants achieved BP control. In HCTZ/atenolol combination antihypertensive therapy, the order in which the drugs are initiated affects total BP lowering during the first 4-6 months of therapy.

Indexed as

AdultAntihypertensive AgentsAtenololBlack PeopleBlood PressureDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesHumansHydrochlorothiazideHypertensionMaleMiddle AgedWhite PeopleAntihypertensive AgentsAtenololHydrochlorothiazide

Identifiers

PMID19571804
PMCPMC2765524

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.